TABLE II.

Base-case results for cost-effectiveness of pazopanib versus placebo

Input	Model
	Partitioned survival (unequal pps and costs of ptact)			Markov cohort (equal pps and costs of ptact)
	Pazopanib	Placebo	Pazopanib vs. placebo	Pazopanib	Placebo	Pazopanib vs. placebo
Effectiveness
Life-years (lys)	1.409	1.294	0.115	1.409	1.166	0.243
Progression-free life-years (pflys)	0.505	0.211	0.294	0.505	0.211	0.294
Post-progression life-years (pplys)	0.904	1.082	−0.179	0.904	0.954	−0.051
Quality-adjusted life-years (qalys)	0.734	0.604	0.130	0.734	0.549	0.184
Effectiveness (discounted)
lys	1.362	1.250	0.112	1.362	1.131	0.231
pflys	0.502	0.211	0.291	0.502	0.211	0.291
pplys	0.859	1.039	−0.179	0.860	0.920	−0.06
qalys	0.713	0.585	0.128	0.713	0.535	0.178
Costs, discounted (CA$)
Direct medical costs (health care system perspective)
Study medication	24,262	0	24,262	24,262	0	24,262
Administration	138	0	138	138	0	138
Adverse events	766	194	572	766	194	572
Other costs, pfs	1,286	541	745	1,286	541	745
Other costs, pps	13,725	18,603	−4,877	13,727	14,036	−308
Total direct medical costs (health care system perspective)	40,177	19,337	20,840	40,179	14,770	25,409
Direct nonmedical and indirect costs (societal perspective)	−4,862	157	−5,019	−4,862	157	−5,018
Total direct and indirect costs (societal perspective)	35,315	19,494	15,821	35,317	14,927	20,391
Cost-effectiveness (CA$)
Health care system perspective
Cost/pflys			71,591			87,288
Cost/lys			186,502			110,043
Cost/qalys			163,336			142,511
Societal perspective
Cost/pflys			54,350			70,047
Cost/lys			141,588			88,308
Cost/qalys			124,001			114,363

pps = post-progression survival; ptact = post-treatment anticancer therapy; pfs = progression-free survival.